KIFC1 induces resistance to docetaxel and is associated with survival of patients with prostate cancer

详细信息    查看全文

• 作者：Yohei Sekino ; M.D.^a ; ^b ; Naohide Oue ; M.D. ; Ph.D.^a ; ^{naoue@hiroshima-u.ac.jp} ; Yoshinori Shigematsu ; M.D.^a ; ^b ; Akira Ishikawa ; M.D.^a ; Naoya Sakamoto ; M.D. ; Ph.D.^a ; Kazuhiro Sentani ; M.D. ; Ph.D.^a ; Jun Teishima ; M.D. ; Ph.D.^b ; Akio Matsubara ; M.D. ; Ph.D.^b ; Wataru Yasui ; M.D. ; Ph.D.^a
• 关键词：Prostate cancer ; KIFC1 ; Cancer stem cells ; Docetaxel
• 刊名：Urologic Oncology: Seminars and Original Investigations
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：35
• 期：1
• 页码：31.e13-31.e20
• 全文大小：1364 K
• 卷排序：35

文摘

About 35% of prostate cancer cases are positive for KIFC1. KIFC1 expression is an independent prognostic indicator of relapse. KIFC1 expression is associated with poor docetaxel-based therapeutic outcomes.